GlassScriptPhysician profile
Suzanne M Cole
NPI 1346333663
$3,541.06
in general payments reported to CMS, 2019-2025
26 companies · $624 in 2025
The $624 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $332 · 2021: $710 · 2022: $693 · 2023: $701 · 2024: $482 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.04 |
| Education | $121.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $606.04 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $451.43 | 2022-2025 | Provenge |
| Seagen INC. | $289.55 | 2022-2023 | Tukysa |
| Foundation Medicine, INC. | $229.43 | 2021-2023 | |
| Procept Biorobotics Corporation | $209.61 | 2021 | |
| Aveo Pharmaceuticals, INC. | $195.34 | 2023-2024 | Fotivda |
| Novartis Pharmaceuticals Corporation | $160.62 | 2023 | |
| Immunitybio, INC. | $150.13 | 2024 | |
| Telix Pharmaceuticals | $148.58 | 2024 | Illuccix |
| Clovis Oncology, INC. | $133.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.25 | 2025 | |
| Daiichi Sankyo INC. | $118.84 | 2024-2025 | Enhertu |
| Exelixis INC. | $107.26 | 2023 | Cabometyx |
| Progenics Pharmaceuticals, INC. | $107.09 | 2022 | |
| Photocure INC | $105.03 | 2025 | Cysview |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $95.68 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $88.00 | 2020 | |
| Gilead Sciences, INC. | $50.16 | 2021-2024 | |
| Tempus Ai, INC | $44.47 | 2024 | |
| Eisai INC. | $26.13 | 2024 | |
| Pfizer INC. | $25.00 | 2023 | |
| Adaptive Biotechnologies Corporation | $24.81 | 2024 | Clonoseq |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Emd Serono, INC. | $19.51 | 2023 | Bavencio |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.